T cell recognition of the MR1 presented microbial metabolome
T 细胞识别 MR1 呈递的微生物代谢组
基本信息
- 批准号:10647681
- 负责人:
- 金额:$ 183.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-10 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAffinity ChromatographyAgonistAnabolismAntigen PresentationAntigenic DiversityAntigensBindingBiologicalBiophysicsBloodBlood donorCD1 AntigensCell TherapyCellsClone CellsCommunicable DiseasesComplementComplexDataDiseaseDisease ResistanceExposure toFolic AcidFolic Acid DerivativeFrequenciesGoalsGrantHealthHigh PrevalenceHumanImmunologyImmunotherapyIndividualInfectionInvadedLigand BindingLigandsLinkLipidsLiverLungMHC Class I GenesMetabolic PathwayMicrobeModelingMolecularMucous MembraneMycobacterium smegmatisMycobacterium tuberculosisNamesNatural ProductsOrganismPathogenicityPathway interactionsPatientsPeptide FragmentsPeripheral Blood Mononuclear CellPhenotypePopulationPopulation HeterogeneityPrevalenceProteinsProtocols documentationPublishingReagentRecombinantsRiboflavinSamplingScienceSignal TransductionSiteStainsStreptococcus pyogenesStructureT cell responseT-Cell ReceptorT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTRANCE proteinTechnologyTestingTissuesTranslatingTuberculosisVaccine TherapyWorkWorld Health Organizationadaptive immunitychemical synthesisfallsimprovedinnovationinnovative technologiesinterestmetabolomemicrobialmigrationmortalitymucosal sitepathogenpathogenic microbeperipheral bloodresponsesensorsmall moleculesocialtargeted treatment
项目摘要
Project Summary/Abstract
Mucosal associated invariant T (MAIT) cells are an innate-like T cell subset prevalent in humans and enriched
in the airway. Human MAIT cells have been defined by the expression of the semi-invariant TCRα chain
TRAV1- 2/TRAJ12/20/33 and their restriction by the non-polymorphic MHC class I-like molecule, MHC-related
protein 1 (MR1). MAIT cells recognize Mtb and can be activated by small organic molecules, derived from the
riboflavin biosynthesis pathway. We have shown that MR1-restricted T cells can use TCRs that are not
TRAV1-2, and can recognize organisms (S. pyogenes) that cannot produce riboflavin. Consequently, we
define MAIT cells as a subset of MR1-restricted T cells (MR1Ts). Furthermore, we find that not all MR1Ts can
be defined based on MR1 tetramer bound to the known MAIT agonist / MR1 ligand 5-(2-oxopropylideneamino)-
6-D- ribitylaminouracil (5-OP-RU), in that they can be defined based on their MR1-dependent response to
microbial infection and binding to alternate MR1 tetramers. We have generated a pipeline approach for
identifying new, microbially-derived MR1 antigens, and demonstrate that MR1Ts in the lung are characterized
by oligoclonal enrichments, possibly driven by these antigens. Together, these data support the specific aims
of this grant which are to 1) define the repertoire of ligands presented by MR1 from M. smeg/Mtb and
define the structural basis of their presentation by MR1. We focus on Mtb for its disease relevance to
human health but also from our preliminary data demonstrating migration of MR1 reactive T cells to the lung
during Mtb infection. Our Aim 2 is to define the T cell repertoire of MR1Ts recognizing antigens
presented by MR1 from M. smeg/Mtb and define the structural basis of their recognition of the MR1-
antigen complex. This is an obvious extension from preliminary data from us and others demonstrating that
the MR1T population contains diversity previously unappreciated. We seek to know whether this diversity in
the TCR repertoire drives antigen selectivity. Directly related to Aims 1 & 2 is our Aim 3 which will determine
the biological significance of MR1-ligand/MR1T cell selectivity in human health and disease. We
hypothesize that MR1T cells with a diverse TCR repertoire selectively expand at infected tissue sites in
response to microbe/ligand recognition via MR1. Here our focus will be on Mtb, and we capitalize on the
expertise and patient accessibility of Dr. Waltz (Capetown) to derive lung (BAL) and PBMC samples from
infected and control individuals. Ultimately, the work from this project would support MR1T cell targeted
vaccines and immune-therapies as a means to improve resistance to disease following exposure to Mtb.
项目总结/摘要
粘液相关不变T(MAIT)细胞是一种在人类中普遍存在的先天性T细胞亚群,
在气道里。人MAIT细胞通过表达半恒定TCRα链来定义
TRAV 1 - 2/TRAJ 12/20/33及其受非多态性MHC I类分子、MHC相关
蛋白1(MR 1)。MAIT细胞识别结核分枝杆菌,并可被来自结核分枝杆菌的小有机分子激活。
核黄素生物合成途径。我们已经证明,MR 1限制性T细胞可以使用不受MR 1限制的TCR。
TRAV 1 -2,并能识别生物体(S.化脓菌)不能产生核黄素。因此我们
将MAIT细胞定义为MR 1限制性T细胞(MR 1 T)的子集。此外,我们发现并非所有的MR 1 T都能
基于与已知MAIT激动剂/MR 1配体5-(2-氧代亚丙基氨基)-
6-D-核糖基氨基尿嘧啶(5-OP-RU),因为它们可以基于它们对
微生物感染和与交替的MR 1四聚体结合。我们已经制定了一个管道方法,
鉴定新的微生物来源的MR 1抗原,并证明肺中的MR 1 T的特征在于
通过寡克隆富集,可能由这些抗原驱动。总之,这些数据支持特定的目标
1)定义由来自M的MR 1呈递的配体库。smeg/Mtb和
定义它们由MR 1表示的结构基础。我们专注于结核分枝杆菌的疾病相关性,
而且我们的初步数据表明MR 1反应性T细胞迁移到肺部
在结核病感染期间。我们的目标2是确定MR 1 Ts识别抗原的T细胞库
由来自M的MR 1呈现。smeg/Mtb,并定义其识别MR 1-
抗原复合物这是我们和其他人的初步数据的明显延伸,
MR 1 T群体包含以前未被认识到的多样性。我们想知道这种多样性是否
TCR库驱动抗原选择性。与目标1和2直接相关的是我们的目标3,它将决定
MR 1-配体/MR 1 T细胞选择性在人类健康和疾病中的生物学意义。我们
假设具有不同TCR库MR 1 T细胞在感染的组织部位选择性扩增,
通过MR 1对微生物/配体识别的响应。在这里,我们的重点将是结核病,我们利用
Waltz博士(开普敦)的专业知识和患者可及性,从
感染者和对照者。最终,该项目的工作将支持MR 1 T细胞靶向
疫苗和免疫疗法作为一种手段,以提高对疾病的抵抗力暴露于结核分枝杆菌。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modulation of riboflavin biosynthesis and utilization in mycobacteria.
分枝杆菌核黄素生物合成和利用的调节。
- DOI:10.1101/2023.08.30.555301
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Chengalroyen,MelissaD;Mehaffy,Carolina;Lucas,Megan;Bauer,Niel;Raphela,MabuleL;Oketade,Nurudeen;Warner,DigbyF;Lewinsohn,DeborahA;Lewinsohn,DavidM;Dobos,KarenM;Mizrahi,Valerie
- 通讯作者:Mizrahi,Valerie
Multiple Isomers of Photolumazine V Bind MR1 and Differentially Activate MAIT Cells.
Photolumazine V 的多种异构体结合 MR1 并差异激活 MAIT 细胞。
- DOI:10.4049/jimmunol.2300609
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Krawic,JasonR;Ladd,NicoleA;Cansler,Meghan;McMurtrey,Curtis;Devereaux,Jordan;Worley,Aneta;Ahmed,Tania;Froyd,Cara;Kulicke,CorinnaA;Swarbrick,Gwendolyn;Nilsen,Aaron;Lewinsohn,DavidM;Adams,ErinJ;Hildebrand,William
- 通讯作者:Hildebrand,William
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erin June Adams其他文献
Erin June Adams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Erin June Adams', 18)}}的其他基金
Investigation into the Endogenous Ligand Repertoire of the Non-Classical MHC-Related Protein, MR1 in Multiple Myeloma Cell Lines
多发性骨髓瘤细胞系中非经典 MHC 相关蛋白 MR1 内源配体库的研究
- 批准号:
10557884 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Molecular and functional investigation of the role of HLA-F in immune regulation
HLA-F在免疫调节中作用的分子和功能研究
- 批准号:
10503676 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Molecular and functional investigation of the role of HLA-F in immune regulation
HLA-F在免疫调节中作用的分子和功能研究
- 批准号:
10636894 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Investigation into the Endogenous Ligand Repertoire of the Non-Classical MHC-Related Protein, MR1 in Multiple Myeloma Cell Lines
多发性骨髓瘤细胞系中非经典 MHC 相关蛋白 MR1 内源配体库的研究
- 批准号:
10452305 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Determining the Origins of Nonclassical Class I molecules through Molecular and Functional Approaches
通过分子和功能方法确定非经典 I 类分子的起源
- 批准号:
10501472 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Determining the Origins of Nonclassical Class I molecules through Molecular and Functional Approaches
通过分子和功能方法确定非经典 I 类分子的起源
- 批准号:
10645114 - 财政年份:2022
- 资助金额:
$ 183.61万 - 项目类别:
Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory
为 Howard T. Ricketts 生物防护实验室提供设施和建筑系统升级支持
- 批准号:
10394614 - 财政年份:2021
- 资助金额:
$ 183.61万 - 项目类别:
Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory
为 Howard T. Ricketts 生物防护实验室提供设施和建筑系统升级支持
- 批准号:
10631368 - 财政年份:2021
- 资助金额:
$ 183.61万 - 项目类别:
Molecular and functional investigation of the role of CD1 in gamma delta T cell surveillance
CD1 在 γ δ T 细胞监测中作用的分子和功能研究
- 批准号:
10670830 - 财政年份:2020
- 资助金额:
$ 183.61万 - 项目类别:
Molecular and functional investigation of the role of CD1 in gamma delta T cell surveillance
CD1 在 γ δ T 细胞监测中作用的分子和功能研究
- 批准号:
10268214 - 财政年份:2020
- 资助金额:
$ 183.61万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 183.61万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 183.61万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 183.61万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 183.61万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 183.61万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 183.61万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 183.61万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 183.61万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 183.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 183.61万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




